Novartis UK awarded Innovation Passport for investigational therapy
Novartis have announced that the investigational oral therapy, iptacopan (LNP023), has been awarded an Innovation Passport for the treatment of C3 glomerulopathy (C3G) by the MHRA, NICE, and the SMC. It is currently being investigated in a number of complement-driven renal diseases(CDRDs), alongside one haematological disorder, for patients with high unmet need.
The Innovation Passport is a designation for innovative medicines. It is the entry point to the Innovative Licensing and Access Pathway (ILAP), a new pathway aiming to accelerate the time taken to market, allowing a more rapid patient access to medicines. A single Innovation Passport can cover multiple future indications for the same active substance.
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor for the alternative pathway of the complement system. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G, and was discovered at the Novartis Institute for BioMedical research. Novartis has a 35-year history in kidney transplantation treatments, however, iptacopan is the first treatment in the nephrology pipeline addressing CDRDs.
Read more: https://www.pharmatimes.com/news/novartis_uk_awarded_innovation_passport_for_investigational_therapy_1382697
The Innovation Passport is a designation for innovative medicines. It is the entry point to the Innovative Licensing and Access Pathway (ILAP), a new pathway aiming to accelerate the time taken to market, allowing a more rapid patient access to medicines. A single Innovation Passport can cover multiple future indications for the same active substance.
Iptacopan is an investigational, first-in-class, orally administered factor B inhibitor for the alternative pathway of the complement system. It has the potential to become the first targeted therapy to delay progression to dialysis in C3G, and was discovered at the Novartis Institute for BioMedical research. Novartis has a 35-year history in kidney transplantation treatments, however, iptacopan is the first treatment in the nephrology pipeline addressing CDRDs.
Read more: https://www.pharmatimes.com/news/novartis_uk_awarded_innovation_passport_for_investigational_therapy_1382697
